Related Experiment Video
Updated: Apr 28, 2026
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance
Brandyn D Henriksbo1, Trevor C Lau1, Joseph F Cavallari1
1Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
Abstract:
Statins reduce lipid levels and are widely prescribed. Statins have been associated with an increased incidence of type 2 diabetes, but the mechanisms are unclear. Activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3)/caspase-1 inflammasome, promotes insulin resistance, a precursor of type 2 diabetes. We showed that four different statins increased interleukin-1β (IL-1β) secretion from macrophages, which is characteristic of NLRP3 inflammasome activation. This effect was dose dependent, absent in NLRP3(-/-) mice, and prevented by caspase-1 inhibition or the diabetes drug glyburide. Long-term fluvastatin treatment of obese mice impaired insulin-stimulated glucose uptake in adipose tissue. Fluvastatin-induced activation of the NLRP3/caspase-1 pathway was required for the development of insulin resistance in adipose tissue explants, an effect also prevented by glyburide. Fluvastatin impaired insulin signaling in lipopolysaccharide-primed 3T3-L1 adipocytes, an effect associated with increased caspase-1 activity, but not IL-1β secretion. Our results define an NLRP3/caspase-1-mediated mechanism of statin-induced insulin resistance in adipose tissue and adipocytes, which may be a contributing factor to statin-induced development of type 2 diabetes. These results warrant scrutiny of insulin sensitivity during statin use and suggest that combination therapies with glyburide, or other inhibitors of the NLRP3 inflammasome, may be effective in preventing the adverse effects of statins.
Insights
Statins activate the NLRP3 inflammasome, leading to insulin resistance. This mechanism may contribute to type 2 diabetes development, suggesting combination therapies could prevent adverse effects.
Area of Science:
- Immunology
- Metabolic Diseases
- Pharmacology
Background:
- Statins are widely prescribed for lipid reduction but are linked to increased type 2 diabetes incidence.
- The underlying mechanisms of statin-associated type 2 diabetes remain unclear.
- NLRP3 inflammasome activation promotes insulin resistance, a precursor to type 2 diabetes.
Purpose of the Study:
- To investigate the role of the NLRP3 inflammasome in statin-induced insulin resistance.
- To elucidate the mechanisms by which statins may contribute to type 2 diabetes.
Main Methods:
- Assessed IL-1β secretion from macrophages treated with four different statins.
- Utilized NLRP3(-/-) mice and caspase-1 inhibition to study inflammasome activation.
- Examined the effects of long-term fluvastatin treatment on insulin sensitivity in obese mice.
- Investigated fluvastatin's impact on insulin signaling in 3T3-L1 adipocytes.
Main Results:
- Statins dose-dependently increased IL-1β secretion, indicating NLRP3 inflammasome activation.
- This effect was absent in NLRP3(-/-) mice and blocked by caspase-1 inhibition or glyburide.
- Long-term fluvastatin impaired insulin-stimulated glucose uptake in adipose tissue of obese mice.
- Fluvastatin-induced insulin resistance in adipose tissue explants and adipocytes was dependent on NLRP3/caspase-1 activation and preventable by glyburide.
Conclusions:
- A NLRP3/caspase-1-mediated mechanism underlies statin-induced insulin resistance in adipose tissue.
- This pathway may contribute to the development of type 2 diabetes in patients using statins.
- Monitoring insulin sensitivity during statin therapy and exploring combination treatments with glyburide or NLRP3 inhibitors are warranted.
Related Concept Videos
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:38Inflammation
01:25Lipid Catabolism